26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
16 December 2024 - BasileaBasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesCeftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…read more >>
25 November 2024 - Centauri Therapeutics LtdCentauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives“We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk…read more >>
21 November 2024 - Debiopharm InternationalCARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae InfectionsNow more than ever, new antibiotics are needed to avoid serious public health consequences caused by this infection.read more >>
13 November 2024 - AktheliaAkthelia Pharmaceuticals featured in Icelandic newspaper ViðskiptablaðiðThe article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring…read more >>
04 November 2024 - PHAXIAMPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.This FDA IND clearance is a major recognition of our therapeutic approach and of our whole platform. This is a…read more >>
30 October 2024 - Thioredoxin Systems ABTXN Systems Raises SEK 25 Million Series A to Advance First-in-Class AntibioticWith its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a…read more >>
07 December 2023GARDP: An innovative public health approach to counter AMRThis webinar will present GARDP’s new five-year strategy, but also highlight our achievements over the past five years in developing…read more >>
16 November 2023Emerging Antimicrobials and Diagnostics in AMR 2023 (EADA 2023)EADA 2023 is the 11th AMR Insights International Matchmaking Symposium on row. The 1,5 day event provides an overview of…read more >>
06 November 2023BIO-EUROPE 2023BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and…read more >>
12 October 2023REVIVE Webinar – Market interventions to improve access to antibiotics for resistant infectionsThis webinar will invite experts in market shaping, describe how market shaping interventions in other areas may be applied to…read more >>
27 September 2023GARDP Webinar: Antibiotic shortages: causes, consequences, and solutionsThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…read more >>
20 September 2023ChinaBio® Partnering Forum 2023ChinaBio® Partnering Forum is the largest and most productive life science partnering conference in China.read more >>
20 September 2023REVIVE Webinar – Clinical trials platforms for new and neglected antimicrobialsThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization, registered under the legal name GARDP Foundation,…read more >>
07 September 2023World AMR CongressSince 2015, the World Anti-Microbial Resistance Congress has been the go-to conference globally for all stakeholders in the AMR space…read more >>
05 September 2023REVIVE Webinar – Starting an antibacterial drug discovery screening programmeThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization, registered under the legal name GARDP Foundation,…read more >>
